Auden Mckenzie

Actavis to acquire Auden Mckenzie for $461.8 million

Monday, January 26, 2015

Actavis, a global specialty pharmaceutical company, will acquire Auden Mckenzie, a company focused on the development, licensing and marketing of niche generic medicines and proprietary brands in the U.K., for approximately $461.8 million in cash, plus a two-year royalty on a percentage of gross profits of one of Auden Mckenzie’s products.

[Read More]